Corrected Headline: RespireRx Pharmaceuticals Up Listed to OTCQB and Ticker Returns to RSPI
February 08, 2021 21:30 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 08, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company” or “we”), has been up listed from the OTC Pink Market and returns to the...
First Patient Implanted in the DREAM US Pivotal IDE Study, with the Genio® System for the Treatment of Obstructive Sleep Apnea (OSA)
November 17, 2020 01:00 ET
|
Nyxoah
First Patient Implanted in the DREAM US Pivotal IDE Study, with the Genio® System for the Treatment of Obstructive Sleep Apnea (OSA) DREAM is a pivotal, Investigational Device Exemption (IDE) study,...
InvestorBrandNetwork (IBN) Coverage Initiated for Vivos Therapeutics Inc.
June 11, 2020 08:30 ET
|
Vivos Therapeutics Inc.
NEW YORK, June 11, 2020 (GLOBE NEWSWIRE) -- via NetworkWire – Vivos Therapeutics Inc., a company focused on addressing the root causes of mild to moderate sleep apnea, today announces it has...
Novel Oral Device a Breath of Fresh Air for Canadian Sleep Apnea Sufferers
March 03, 2020 08:41 ET
|
Oventus Medical Ltd
TORONTO, March 03, 2020 (GLOBE NEWSWIRE) -- Canadians living with obstructive sleep apnea (OSA) who are frustrated with cumbersome and uncomfortable CPAP machines can breathe easier thanks to an...
Nyxoah raises €25 million in private funding round
February 13, 2020 07:58 ET
|
Nyxoah
Nyxoah raises €25 million in private funding round Mont-Saint-Guibert, Belgium – 12 February 2020, Nyxoah S.A., a healthtech company developing neuromodulation-based therapeutic solutions for sleep...
RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Directors
February 03, 2020 09:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J, Feb. 03, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...
Sleep Tech Devices Market value to cross $27 billion by 2025: Global Market Insights, Inc.
November 05, 2019 05:00 ET
|
Global Market Insights, Inc
Selbyville, Delaware, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Global Sleep Tech Devices Market is projected to surpass USD 27 billion by 2025, according to a new research report by Global Market...
RespireRx Pharmaceuticals Inc. and Impression Healthcare Limited Announce Agreement to Explore Commercialization of Dronabinol for the Treatment of Obstructive Sleep Apnea (OSA) in Australia, New Zealand and Southeast Asia
February 19, 2019 08:50 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...
RespireRx Pharmaceuticals Inc. Secures Clinical and Commercial Supply of Dronabinol for Obstructive Sleep Apnea with the Signing of a Development and Supply Agreement with Noramco, Inc.
September 10, 2018 15:30 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- September 10, 2018 /Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that on...
Advancing Dronabinol Obstructive Sleep Apnea Program with Letter of Intent for Co-Development and Supply Agreement with Noramco, Inc.
June 19, 2018 08:45 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., June 19, 2018 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that on June 13, 2018, it entered into a letter...